(CPRX) Catalyst Pharmaceuticals, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CPRX) Catalyst Pharmaceuticals, Inc. Complete Analysis Pack
Catalyst Pharmaceuticals: Rare-Disease Strategy Driving Durable Value
Discover how Catalyst Pharmaceuticals, Inc. turns a focused rare-disease strategy into durable value creation. This Business Model Canvas breaks down the company’s key partners, revenue drivers, customer segments, and cost structure in a clear, actionable format. Get the full version to sharpen your analysis and spot the opportunities behind its growth.
Partnerships
BioMarin Pharmaceutical license
BioMarin supplied the amifampridine phosphate asset behind Firdapse, and Catalyst Pharmaceuticals, Inc. built its U.S. rare-disease franchise on that license. In 2025, Firdapse remained Catalyst Pharmaceuticals, Inc.'s core product, with net product revenue of about $429 million, showing how central this partnership is to the business model.
Endo Ventures Limited Sabril agreement
Endo Ventures Limited’s Sabril agreement gives Catalyst Pharmaceuticals, Inc. a third neurology revenue stream through joint development and commercialization of generic Sabril tablets, adding to the Firdapse and Ruzurgi base. That matters because it diversifies income across 3 products and reduces reliance on one rare-disease franchise.
Specialty pharmacy network
Specialty pharmacy network partners help Catalyst Pharmaceuticals, Inc. move ultra-rare-disease oral medicines to patients, with tighter access checks, refill coordination, and direct shipment. This channel fits chronic therapy because steady refill flow matters more than one-time fills, and it supports adherence for long-term use.
Contract manufacturing partners
Catalyst Pharmaceuticals, Inc. uses contract manufacturing partners for drug substance and finished-dose supply, so it does not need to own large-scale plants. This setup matters for FDA-regulated commercial continuity, because even one supply break can hit patient access and revenue fast.
- Outsources API and finished-dose supply
- Reduces capital tied in plants
- Supports FDA-compliant continuity
Clinical investigators and rare-disease centers
Clinical investigators and rare-disease centers are key to Catalyst Pharmaceuticals, Inc. because specialist sites recruit and follow patients with LEMS and other neuromuscular disorders, where cases are scarce and data are hard to gather. These partners help test new uses for Firdapse and support label expansion across a 2025-2026 pipeline built on the same rare-disease network.
Specialist sites enable rare-patient enrollment
They support Firdapse label expansion
They feed Catalyst Pharmaceuticals, Inc. pipeline data
Firdapse Partners Power $429M Revenue in 2025
Key partnerships center on BioMarin, Endo Ventures Limited, specialty pharmacies, contract manufacturers, and rare-disease sites. In 2025, Firdapse generated about $429 million of net product revenue, while outsourced supply and patient-distribution partners kept access, compliance, and scale in place.
| Partner | Role | 2025 value |
|---|---|---|
| BioMarin | Firdapse asset | $429 million revenue |
| Endo Ventures Limited | Sabril deal | 3-product base |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas showing how Catalyst Pharmaceuticals creates, delivers, and captures value through specialty rare-disease therapies.
Customizable Excel Spreadsheet
Helps quickly map Catalyst Pharmaceuticals’ business model pain points in a clear, editable one-page view.
Reference Sources
Provides a credible source trail for Catalyst Pharmaceuticals, Inc., helping decision-makers verify assumptions fast and trust the analysis.
Activities
Commercialize Firdapse
Catalyst Pharmaceuticals, Inc. centers its commercial engine on Firdapse, its flagship product for Lambert-Eaton myasthenic syndrome, a rare disease affecting about 3 per 1,000,000 people. In 2025, that means the company’s cash flow still depends on high-touch physician adoption, payer access, and steady patient supply.
Commercial execution matters because every new start and refill supports recurring revenue from a small patient base, so sales, reimbursement, and distribution are core value drivers for Catalyst Pharmaceuticals, Inc.
Support Ruzurgi availability
Catalyst keeps Ruzurgi available for pediatric LEMS, a very small ultra-rare market, by managing FDA compliance, specialty distribution, and physician support. In 2024, Catalyst reported $457.4 million in net product sales, and Ruzurgi helps extend its rare-disease footprint beyond adult LEMS.
Run label-expansion research
Catalyst Pharmaceuticals, Inc. is running label-expansion research on Firdapse beyond Lambert-Eaton myasthenic syndrome, with work in MuSK antibody positive myasthenia gravis, SMA type 3, and HNPP. Testing 3 new neuromuscular uses could widen Firdapse’s addressable market and add more than one future revenue stream.
Maintain regulatory compliance
Catalyst Pharmaceuticals, Inc. has to keep FDA compliance tight across every step of the drug lifecycle: labeling, adverse-event reporting, quality systems, and promotion. In 2025, that means constant oversight because one missed safety update or label change can affect every prescription, recall risk, and revenue stream.
- Labeling and safety reporting
- Quality-system controls
- Promotional review
- Ongoing FDA monitoring
This work is non-negotiable, and it stays on all year.
Manage supply and launch operations
Catalyst coordinates forecasting, inventory, packaging, and replenishment for rare-disease drugs like Firdapse, used by about 3,000 people in the United States with Lambert-Eaton myasthenic syndrome. In a small, chronic patient base, a missed batch can disrupt therapy, so launch execution and steady supply directly protect patient continuity.
- Forecast demand tightly
- Keep inventory ready
- Package and replenish on time
- Protect chronic treatment continuity
Catalyst’s Core: Firdapse Sales, FDA Compliance, and Expansion
Catalyst Pharmaceuticals, Inc.’s key activities are commercializing Firdapse and Ruzurgi, keeping FDA compliance tight, and running label-expansion studies in neuromuscular diseases. In 2024, net product sales were $457.4 million, with demand tied to about 3,000 U.S. LEMS patients.
| Key activity | 2024 data |
|---|---|
| Net product sales | $457.4 million |
| U.S. LEMS patients | ~3,000 |
Preview Before You Purchase
Business Model Canvas
This preview of the Catalyst Pharmaceuticals, Inc. Business Model Canvas is not a sample or mockup—it’s a direct view of the exact document you’ll receive after purchase. What you see here is the same professionally formatted file, with the same content and layout, ready for immediate use. Once you buy, you’ll get full access to this identical document.
Resources
FDA-approved products
Firdapse and Ruzurgi are Catalyst Pharmaceuticals, Inc.'s FDA-approved commercial assets, giving it immediate access to the rare-disease market. In FY2025, approved products remained the main revenue engine, with net product sales near the $500 million level, led by Firdapse in Lambert-Eaton myasthenic syndrome.
Amifampridine phosphate rights
Amifampridine phosphate rights are Catalyst Pharmaceuticals, Inc.'s core asset, because the platform behind FIRDAPSE anchors its lead therapy strategy and protects the company's market position through IP and licensing. In 2025, this resource still sat at the center of Catalyst Pharmaceuticals, Inc.'s business model and revenue mix, making control of the rights the key value driver.
Rare-disease regulatory expertise
Catalyst Pharmaceuticals, Inc. has built rare-disease regulatory expertise through orphan-drug filings and post-approval work for tiny patient pools, like Lambert-Eaton myasthenic syndrome, which affects about 3 per 1,000,000 people. That know-how helps Catalyst secure approvals, win label changes, and stay compliant where even small regulatory wins can matter.
Commercial field organization
Catalyst Pharmaceuticals, Inc. relies on a focused commercial field organization because rare-disease sales depend on specialist engagement, not mass marketing. The sales and medical affairs teams drive physician awareness, shape diagnosis, and support uptake in narrow patient pools where each prescriber matters.
- Targets rare-disease specialists
- Builds physician awareness
- Supports medical education
- Drives product adoption
Cash generated from product sales
Cash from product sales is Catalyst Pharmaceuticals, Inc.’s core fuel for research, launches, and rare-disease execution. In the latest reported year, the company kept a self-funding model with product revenue of about $480 million and positive operating cash flow, which lowers reliance on outside capital and protects strategic flexibility.
- Funds R&D and commercial work
- Supports a self-funding rare-disease model
- Reduces need for external financing
FIRDAPSE and amifampridine drive Catalyst’s cash engine
Key resources are Catalyst Pharmaceuticals, Inc.'s FDA-approved rare-disease products, especially FIRDAPSE, plus the amifampridine rights that anchor its IP. In FY2025, net product sales were about $480 million to $500 million, showing the asset base still drives cash and growth.
| Resource | FY2025 signal |
|---|---|
| FIRDAPSE | Main revenue driver |
| Amifampridine rights | Core IP asset |
| Cash from sales | Self-funding model |
Value Propositions
FDA-approved LEMS therapy
Firdapse is Catalyst Pharmaceuticals, Inc.’s FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome, a rare and serious neuromuscular disorder affecting about 3 per 1,000,000 people. As the only approved LEMS therapy in the U.S., it is the company’s core patient value.
Pediatric LEMS option
Ruzurgi gives Catalyst Pharmaceuticals, Inc. a pediatric LEMS option for patients ages 6 to 17, filling a rare-disease gap where treatment choices are scarce. That age-specific reach helps extend Catalyst Pharmaceuticals, Inc. across the full LEMS population and supports a differentiated value proposition in a niche market.
US-focused rare-disease access
Catalyst Pharmaceuticals, Inc. focuses on US rare diseases such as Lambert-Eaton myasthenic syndrome and congenital myasthenic syndromes, where patient counts are small but unmet need is high. That lets it run a narrow, specialist commercial model built for hard-to-find patients, long-term therapy use, and payer access in low-prevalence markets.
Chronic oral therapy convenience
Firdapse is an oral tablet, so patients with chronic neuromuscular disease can use it at home instead of relying on infusions or clinic visits. That matters for long-term outpatient care: oral dosing is simpler to follow, and in Catalyst Pharmaceuticals, Inc.'s latest reporting, Firdapse remained its core branded product for Lambert-Eaton myasthenic syndrome.
- Oral tablet for chronic use
- Supports outpatient adherence
- Reduces treatment burden
Pipeline for new indications
Catalyst Pharmaceuticals, Inc. is extending Firdapse beyond its current labeled use, so one approved asset can reach more patients without the cost and risk of inventing a new molecule. That gives the Company a scalable upside path if later studies support new rare-disease uses.
- One core asset, more patient reach
- Lower risk than a new molecule
- Upside depends on trial success
Catalyst’s Rare-Disease Edge: The Only U.S. LEMS Therapy
Catalyst Pharmaceuticals, Inc. wins on rare-disease access: Firdapse is the only FDA-approved U.S. LEMS therapy, and Ruzurgi serves ages 6 to 17. The value is simple: oral, home use, low patient counts, and high unmet need.
| Asset | Value proposition | Key fact |
|---|---|---|
| Firdapse | Core adult LEMS therapy | Only U.S.-approved LEMS drug |
| Ruzurgi | Pediatric LEMS access | Ages 6 to 17 |
Customer Relationships
Specialist-led engagement
Catalyst Pharmaceuticals, Inc. depends on a small set of neurologists and neuromuscular specialists, so the relationship is highly consultative, not mass-market. In 2025, that specialist-first model fit a business built around 2 core rare-disease therapies, where prescribers need trial data, dosing detail, and safety updates, not consumer ads.
Patient support hubs
Patient support hubs help people start and stay on Catalyst Pharmaceuticals, Inc. therapy by handling benefits verification, refill coordination, and access steps that matter in rare disease care, where fewer than 200,000 U.S. patients may be affected by each condition. These hubs reduce drop-off after prescribing and support steady treatment use.
Reimbursement assistance
Catalyst Pharmaceuticals, Inc. uses high-touch reimbursement support to help with prior authorization and payer coverage, which matters in rare disease where treatment starts can stall fast. With 2 key marketed therapies, reducing approval friction is central to driving initiation and keeping patients on therapy.
Medical information support
Catalyst Pharmaceuticals, Inc.'s medical affairs team gives product and disease-state info that helps specialists use treatments safely and prescribe on evidence, not guesswork. Fast answers matter in rare disease care, where even a small delay can affect treatment decisions.
- Supports safer use and dosing
- Backs evidence-based prescribing
- Answers specialist questions fast
Long-term therapy follow-up
LEMS is a chronic, ultra-rare disease, with prevalence estimated at about 3 per million people, so Catalyst Pharmaceuticals, Inc. relies on long-term follow-up to support persistence, safety, and adherence to FIRDAPSE in a small, specialized patient base. That ongoing touchpoint helps keep therapy on track as symptoms and dosing needs can change over time.
- Chronic use needs steady follow-up
- Safety checks support adherence
- Specialized care fits rare-disease scale
Catalyst’s Rare-Disease Growth Runs on High-Touch Patient Support
Catalyst Pharmaceuticals, Inc. keeps customer ties highly consultative: 2025 sales depended on specialist neurologists, while patient hubs and reimbursement support reduced prior-auth delays and refill drop-off. In rare disease, that high-touch model matters because each start can depend on fast coverage and dosing help.
| Driver | 2025 fact |
|---|---|
| Core therapies | 2 marketed drugs |
| LEMS prevalence | ~3 per million |
| Support model | Hub, PA, medical affairs |
Channels
Specialty pharmacy distribution
Specialty pharmacy distribution is a fit for Catalyst Pharmaceuticals, Inc. because its rare-disease drugs need low-volume, high-touch fulfillment. These pharmacies handle cold-chain shipping, refill timing, and patient coordination, which supports therapy starts and ongoing adherence for products like rare-disease treatments.
Neurologist sales calls
Catalyst Pharmaceuticals, Inc. uses a focused field team to call neurologists directly, making specialist outreach its main demand-generation channel. In 2025, this is the most efficient path because Catalyst Pharmaceuticals sells rare-disease neurology products to a narrow prescriber base, so one specialist call can reach more likely prescribers than broad consumer advertising.
Patient access hub
Catalyst Pharmaceuticals, Inc.'s patient access hub links patients, prescribers, and payers, so new prescriptions move from writing to dispensing faster. By supporting benefits checks, prior auth, and refill follow-up, it helps drive initiation and persistence across the 3 key steps in therapy access.
Payer and reimbursement teams
Catalyst Pharmaceuticals, Inc. relies on payer and reimbursement teams to win coverage from insurers and managed care organizations, since orphan drugs serve fewer than 200,000 U.S. patients and access can hinge on formulary placement and prior authorization. These teams work to show clinical value and reduce out-of-pocket friction, which is key for uptake in narrow patient pools.
- Coverage drives orphan-drug access.
- Formulary status shapes uptake.
- Reimbursement support lowers friction.
Medical congresses and scientific outreach
Catalyst Pharmaceuticals, Inc. uses medical congresses and scientific outreach to reach neuromuscular specialists, especially in rare disease care. These meetings help build awareness of LEMS and support discussion of pipeline studies, which matters in a niche market where specialist education drives diagnosis and treatment.
- Targets rare-disease specialists
- Raises LEMS awareness
- Supports pipeline education
Catalyst’s Rare-Disease Access Engine: Specialty Pharmacies, Support, and Reach
In 2025, Catalyst Pharmaceuticals, Inc. leans on specialty pharmacies, a focused neurologist sales force, and a patient access hub to move rare-disease prescriptions with less friction. Payer support and congress outreach help protect access and educate neuromuscular specialists across a small prescriber base.
| Channel | Role |
|---|---|
| Specialty pharmacy | Dispense and adherence |
| Field force | Neurologist outreach |
| Access hub | Benefits and prior auth |
| Payer team | Coverage support |
Customer Segments
Adult LEMS patients
Adult LEMS patients are Catalyst Pharmaceuticals, Inc.’s core Firdapse market: Lambert-Eaton myasthenic syndrome is ultra-rare, at about 3 cases per 1 million people, and adults make up the approved treatment population. Because symptoms are chronic and ongoing, this segment drives repeat use and remains the primary patient base for long-term revenue.
Pediatric LEMS patients
Pediatric LEMS patients are a very small but clinically important niche, in a disease seen in about 3 to 5 people per million. Catalyst Pharmaceuticals, Inc.'s Ruzurgi was designed for children ages 6 to 17, meeting a rare need where treatment options are limited.
Neurologists and neuromuscular specialists
Neurologists and neuromuscular specialists are Catalyst Pharmaceuticals, Inc.'s main prescribers because they diagnose and manage rare disorders such as Lambert-Eaton myasthenic syndrome, a disease affecting about 3 per 1 million people. Their buy-in drives script volume, since treatment decisions are concentrated in a small number of specialty clinics and hospital systems.
That makes education and peer trust critical: in rare-disease care, a few high-prescribing specialists can shape most product use and refill persistence.
US payers and managed care plans
US payers and managed care plans are Catalyst Pharmaceuticals, Inc.'s key economic gatekeepers because they decide access, prior authorization, and patient out-of-pocket costs for rare-disease drugs. With U.S. health spending at about $5.1 trillion in 2024 and specialty drugs driving a growing share, coverage rules can make or break uptake for therapies like Catalyst Pharmaceuticals, Inc.'s.
Control formulary access and step edits.
Shape prior authorization and copay burden.
Coverage is decisive in rare diseases.
Hospitals and specialty clinics
Hospitals and specialty clinics are Catalyst Pharmaceuticals, Inc.'s key front end for rare-disease care: they diagnose patients, start treatment, and send prescriptions through a small network of specialist prescribers. These sites also drive research enrollment in ultra-rare diseases, where the patient pool is tiny, like Lambert-Eaton myasthenic syndrome, estimated at about 3 per 1 million people.
They matter because one well-placed center can influence referral flow, treatment starts, and trial access across a whole region.
- Diagnose rare disorders
- Start therapy early
- Refer and prescribe
- Support trial enrollment
Catalyst’s Rare-Patient Revenue Depends on a Few Key Gatekeepers
Catalyst Pharmaceuticals, Inc. serves ultra-rare LEMS patients, mainly adults, plus the small pediatric niche for Ruzurgi. The buying path is narrow: neurologists, neuromuscular specialists, hospitals, and US payers decide diagnosis, prescribing, and access, so a few sites and plans shape most revenue.
| Segment | Role | Key fact |
|---|---|---|
| Patients | Use therapy | LEMS: ~3/million |
| Specialists | Prescribe | High-concentration |
| Payers | Approve access | Coverage is decisive |
Cost Structure
Sales and marketing expense
Catalyst Pharmaceuticals, Inc. must fund a specialist sales team and patient support for rare-disease drugs, so sales and marketing is a major cost. In 2024, selling, general and administrative expense was about $116.5 million, showing how much the Company spends on targeted outreach, reimbursement help, and physician education.
Research and development expense
Catalyst Pharmaceuticals, Inc. spent about $21 million on research and development in 2024, funding clinical studies that can win new Firdapse uses and extend the platform beyond its current rare-disease base. That spend is the core bet on long-term growth: label expansion needs capital now, but it can add durable revenue later.
Manufacturing and supply costs
Catalyst Pharmaceuticals pays for production, packaging, testing, and inventory control to keep chronic therapies in steady 30-day refill cycles. Because supply must stay reliable, these costs rise with sales volume: a 10% increase in demand typically means about 10% more batch work, quality checks, and stock handling.
Regulatory and quality costs
Regulatory and quality costs are a structural part of Catalyst Pharmaceuticals, Inc.’s model because FDA compliance needs validated quality systems, adverse-event reporting, and routine audits. In rare-disease drugs, post-approval duties do not stop at launch; they keep running through lifecycle monitoring, inspections, and remediation if needed.
- Quality systems are mandatory
- Post-approval reporting continues
- Audit and inspection costs recur
- Not optional, but built in
Royalty and license obligations
Firdapse-origin rights and other licensed assets can carry ongoing royalty or milestone payments, so Catalyst Pharmaceuticals, Inc. must share part of product economics with licensors. That cuts into gross margin because each dollar of licensed sales can still trigger contract costs before operating profit.
- Royalty costs reduce licensed-product margin.
- Milestones hit cash flow when triggered.
- Partner terms shape Firdapse economics.
Cost Burden: SG&A, R&D, and Royalties Weigh on Margins
Cost structure is dominated by commercial reach, compliance, and product development: Catalyst Pharmaceuticals, Inc. reported about $116.5 million of SG&A and $21 million of R&D in 2024. Manufacturing, quality, and post-approval oversight stay recurring, while licensed assets can add royalty and milestone costs that trim margin.
| Cost item | 2024 |
|---|---|
| SG&A | $116.5M |
| R&D | $21.0M |
| Royalty/milestone burden | Ongoing |
Revenue Streams
Firdapse net product sales
In 2025, Firdapse remained Catalyst Pharmaceuticals, Inc.'s core revenue engine, with U.S. net product sales tied to its approved Lambert-Eaton myasthenic syndrome (LEMS) indication. Because LEMS is a rare, chronic condition, this is a recurring prescription stream that anchors the Company Name's top line.
Ruzurgi net product sales
Ruzurgi added pediatric LEMS revenue by serving the 6–17 age group, a rare market tied to Lambert-Eaton myasthenic syndrome, which affects about 3 people per million. It complemented Firdapse’s adult sales and broadened Catalyst Pharmaceuticals, Inc.’s commercial base in a small but high-value orphan segment.
Collaboration revenue
Catalyst Pharmaceuticals, Inc. can recognize collaboration revenue from partnership arrangements, including the Endo Ventures Sabril deal. This stream adds diversification beyond direct product sales and can smooth results when product demand shifts.
Milestone and license income
Milestone and license income is usually irregular but high-margin, because biopharma deals can pay when Catalyst Pharmaceuticals, Inc. hits regulatory, clinical, or sales targets. This is non-product revenue, and in the sector it often comes as upfront cash plus milestone checks that can range from millions to hundreds of millions per deal, even when product sales stay the main engine.
- Pay on FDA, launch, or sales milestones
- Supports non-product revenue and cash flow
- Common in biopharma partnering deals
Future indication expansion sales
If Catalyst Pharmaceuticals, Inc. wins new Firdapse uses, it can add product revenue beyond its approved Lambert-Eaton myasthenic syndrome label. The main upside sits in MuSK antibody positive myasthenia gravis and SMA type 3, making indication expansion the key long-term growth path for Firdapse.
- 2 pipeline targets
- New uses can lift sales
- Growth beyond current label
Catalyst’s 2025 Revenue: Firdapse Leads, Milestones Add Lift
In 2025, Catalyst Pharmaceuticals, Inc.'s revenue still came mainly from Firdapse, its rare-disease LEMS drug, with Ruzurgi adding pediatric sales and partner revenue adding a smaller, steadier layer. Milestones and license income stayed lumpy, but they lift margin when deals hit.
| Stream | 2025 role | Key fact |
|---|---|---|
| Firdapse | Main driver | Adult LEMS |
| Ruzurgi | Secondary | 6–17 LEMS |
| Partner/milestone | Non-product | Irregular cash |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.